How the FDA Impacts the Parkinson's Community
This informational webcast provides a unique opportunity to gain valuable insights into the FDA, the role it plays in therapy development, and possible areas for needed change and improvement.
Click here to watch a recorded archive of the webcast.
Amy Comstock Rick, JD
CEO, Parkinson's Action Network
Marc Walton, MD, PhD
Associate Director for Translational Medicine in the Office of Translational Sciences at the Center for Drug Evaluation and Research, FDA
Michelle McMurry-Heath, MD, PhD
Associate Director for Science at the Center for Devices and Radiological Health, FDA
Cartier Esham, PhD
Senior Director of Emerging Companies Health and Regulatory Affairs for the Biotechnology Industry Organization (BIO)
Patient-Representative to the Food and Drug Administration's Office of Special Health Issues
This program is made possible by a conference support grant awarded from and administered by the Telemedicine & Advanced Technology Research Center (TATRC) of the U.S. Army Medical Research & Materiel Command (USAMRMC), Award # W23RYX1067N603
This webcast was made possible in part by a grant from UCB.
With additional contributions from: